Fulcrum Therapeutics   Report issue

For profit Phase 1 Phase 3
Founded: Cambridge MA United States (2016)

Organization Overview

First Clinical Trial
2019
NCT04003974
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Fulcrum Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

losmapimod (5 trials)

Drugs in Phase 1 Trials (2)

ftx-6058 (2 trials)

midazolam (versed) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Facioscapulohumeral (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3